""

about | Maps & Directions | contact | admissions | faculty | alumni & development | library | Tech Support Center | dean's office | Policies & Procedures

. . .

CENTER FOR INFLAMMATION, TRANSLATIONAL AND CLINICAL LUNG RESEARCH (CILR)

Research Interests

 

Basic and Pre-Clinical Research Interests
  • Acute lung injury
  • Asthma
  • Cell death/apoptosis
  • Chronic Obstructive Pulmonary Disease
  • Cytokines and chemokines
  • Cytokine and chemokine receptors
  • Dendritic cell biology
  • Endothelial cell biology
  • Epithelial cell biology
  • G protein-coupled receptors
  • Inflammation
  • Innate and acquired immunity
  • Interstitial pulmonary fibrosis
  • Lung cancer
  • Lung transplantation
  • Mucin expression and immunomodulatory activity
  • Neutrophil biology
  • Monocyte and macrophage biology
  • Protein kinase C immunoregulatory activity
  • Pulmonary arterial hypertension
  • Pulmonary fibrosis
  • Sarcoidosis
  • T cell regulation

 

Clinical and Translational Research Activities

 

  • Multi-Institutional Research Studies: Temple Lung Center typically has over 25 open clinical research studies at any one time. These include: COPD, emphysema, pulmonary fibrosis, sarcoidosis, lung cancer, respiratory failure, lung transplantation, and pulmonary arterial hypertension.  Multiple COPD studies include: COPD Gene, Long Term Oxygen Treatment Trial (LOTT), COPD Clinical Research Network and multiple pharmaceutical and interventional COPD trials (AERIS and VENT). In the NHLBI COPD Clinical Research Network, Temple is the highest single center enroller for all three CRN clinical trials; MACRO, LEUKO and PREVNAR. In COPD Gene, Temple is the highest enrolling site with over 966 patients enrolled over a 18 month enrollment period; 697/966 (72%)  are AA, 419/966 (43%) are female. These studies bring new patients to campus for novel care.
  • Clinical Trials: A total of 6 clinical trials and registries for IPF are currently ongoing at Temple (PA-DOH IPF Registry, NHLBI COMET: Correlating outcomes with Biochemical Markers to Estimate time-Progression in IPF, NHLBI Genomic and Proteomic Analysis of Disease Progression in IPF, Efficacy & Safety of IV CNTO 888 in IPF, Efficacy & Safety of Macitentan in IPF, Efficacy & Safety of Ambristetan in IPF) which draws large numbers of IPF patients to our campus for evaluation, diagnosis and therapy.
  • Interface Between Clinical Research and Patient Treatment: These studies are a reason why in large part our practice for patients with COPD and IPF is large and growing. We have cared for 27,376 unique COPD patients in the past 5 years; 39% of these COPD patients were African American and 53% were female. Temple has treated 4,656 unique IPF patients over the past 5 years (624-1317patients/year; >30% are African American, 55% female) with a 50% increase in the number of IPF patients treated yearly over the past 3 years.